期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌两周方案新辅助化疗临床研究

原文传递
导出
摘要 目的探讨使用以蒽环类药物新辅助化疗2周方案(14d为1周期)替代传统3周方案(21d为1周期)应用价值。方法66例原发性乳腺癌患者随机分为两组,32例使用2周方案,34例使用3周方案,比较化疗疗效和毒副作用。结果两组有效率分别为93.3%与88.2%,缓解率差异无统计学意义(P>0.05)。各种毒副作用的发生率相比差异无统计学意义(P>0.05)。结论2周方案与3周方案在术前新辅助化疗近期临床效果相同,毒副作用比较差异无统计学意义,且能够缩短患者化疗时间,是一种有效可行的化疗方案。
作者 贾国丛 宋再
机构地区 郑州市中心医院乳腺外科
出处 《肿瘤研究与临床》 CAS 2006年第7期475-476,共2页 Cancer Research and Clinic
关键词 蒽环类药物 新辅助化疗 乳腺癌
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献5

  • 1张斌.乳腺癌的新辅助化疗[J].中华肿瘤杂志,2003,25(3):209-211. 被引量：72
  • 2Mauriac L, Durand M, Avril A, et al. Effects of primary chemotherapsy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre[J]. Ann Oncol, 1991, 2(5): 347-354.
  • 3李金锋,欧阳涛,王天峰,林本耀.原发性乳腺癌新辅助化疗的临床研究[J].中华肿瘤杂志,2004,26(8):493-495. 被引量：43
  • 4Spielmann M, Kerbrat P, Delozier T, et al. Pirarubicin in advanced breast cancer: a French cooperative phase II study[J]. Eur J Cancer,1990, 26(7): 821-823.
  • 5Amat S, Leduc B, Chollet P, et al. Clinical and pahtological response to primary chemotherapy in operable breast cancer[J]. Eur J Cancer,1997, 33(6): 862-866.

二级参考文献19

  • 1Bhalla K, Harris WB. Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer. Semin Oncol, 1998, 25 (2 suppl 3): 19-24.
  • 2Kuerer HM, Newman LA, Buzder AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg, 1998, 176:502-509.
  • 3Ellis P, Smith I, Ashley S, et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol, 1998, 16:107-114.
  • 4Cameron DA, Anderson ED, Levack P, et al. Primary systemic therapy for operable breast cancer - 10 - year survival data after chemotherapy and hormone therapy. Br J Cancer, 1997, 76:1099-1105.
  • 5Pierga JY, Mouret E, Dieras V, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer, 2000, 83: 1480-1487.
  • 6Hutcheon AW, Heys SD, Miller ID, et al. Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: a randomised controlled trial. Breast Cancer Res Treat, 2001, 69: 298.
  • 7Chang J, Ormerod M, Powles TJ, et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer, 2000, 89: 2145-2152.
  • 8Bottini A, Berruti A, Bersiga A, et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res, 2000,6: 2751-2758.
  • 9Akashi-Tanaka S, Fukutomi T, Watanabe T, et al. Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy. Int J Cancer, 2001, 96: 66-73.
  • 10Huber S, Medl M, Vesely M, et al. Ultrasonographic tissue characterization in monitoring tumor response to neoadjuvant chemotherapy in locally advanced breast cancer (work in progress). J Ultrasound Med, 2000, 19: 677-686.

共引文献104

肿瘤研究与临床
2006年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部